scholarly journals Case Report: Gastric Mucormycosis- a rare but important differential diagnosis of upper gastrointestinal bleeding in an area of Helicobacter pylori endemicity

2019 ◽  
Vol 4 ◽  
pp. 5
Author(s):  
Sudeep Adhikari ◽  
Ajaya Raj Gautam ◽  
Buddhi Paudyal ◽  
Keshav Raj Sigdel ◽  
Buddha Basnyat
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Early Recognition ◽  
Early Stage ◽  
Eradication Therapy ◽  
Immunocompromised Host ◽  
Complete Recovery ◽  
H Pylori ◽  
Upper Gastrointestinal

A 57 years female from the hills of Nepal presented with upper gastrointestinal bleeding with gastric ulcer evident on endoscopy. Though initially treated with Helicobacter pylori (H. pylori) eradication therapy alone, biopsy later on revealed both mucormycosis and H. pylori infection. She was then treated with antifungals liposomal amphotericin B followed by posaconazole which led to complete recovery. Mucormycosis is a rare but life-threatening fungal disease of immunocompromised host though our patient was immunocompetent. If recognized and treated at early stage, as in our patient, prognosis is good. A high index of suspicion is required for considering this disease in H. pylori endemic regions such as Nepal, and is crucial for early recognition and treatment.

scholarly journals Case Report: Gastric Mucormycosis- a rare but important differential diagnosis of upper gastrointestinal bleeding in an area of Helicobacter pylori endemicity

2019 ◽  
Vol 4 ◽  
pp. 5 ◽  
Author(s):  
Sudeep Adhikari ◽  
Ajaya Raj Gautam ◽  
Buddhi Paudyal ◽  
Keshav Raj Sigdel ◽  
Buddha Basnyat
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Early Recognition ◽  
Early Stage ◽  
Eradication Therapy ◽  
Immunocompromised Host ◽  
Complete Recovery ◽  
H Pylori ◽  
Upper Gastrointestinal

A 57 years female from the hills of Nepal presented with upper gastrointestinal bleeding with gastric ulcer evident on endoscopy. Though initially treated with Helicobacter pylori (H. pylori) eradication therapy alone, biopsy later on revealed both mucormycosis and H. pylori infection. She was then treated with antifungals liposomal amphotericin B followed by posaconazole which led to complete recovery. Mucormycosis is a rare but life-threatening fungal disease of immunocompromised host though our patient was immunocompetent. If recognized and treated at early stage, as in our patient, prognosis is good. A high index of suspicion is required for considering this disease in H. pylori endemic regions such as Nepal, and is crucial for early recognition and treatment.

scholarly journals Epidemiology of upper gastrointestinal bleeding and Helicobacter pylori infection: review of 3,488 Thai patients

2017 ◽  
Vol 9 (1) ◽  
pp. 87-93
Author(s):  
Sakolwan Suchartlikitwong ◽  
Kamolyut Lapumnuaypol ◽  
Rungsun Rerknimitr ◽  
Duangporn Werawatganon
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Helicobacter Pylori Infection ◽  
Exclusion Criteria ◽  
Common Causes ◽  
Mucosal Lesions ◽  
H Pylori ◽  
Upper Gastrointestinal

Abstract Background The current epidemiology of upper gastrointestinal bleeding (UGIB) in Thailand is poorly understood and the reported prevalence of Helicobacter pylori infection is outdated. Objectives To investigate the etiologies of UGIB and prevalence of H. pylori infection in Thailand, including its association with UGIB. Methods We retrieved information regarding patients attending the endoscopic unit of King Chulalongkorn Memorial Hospital from June 2007 to January 2013. A database search using keywords “upper gastrointestinal bleeding” and “iron deficiency” was used. From 4,454 diagnoses, after exclusion criteria, 3,488 patients (2,042 male (58.5%) and 1,446 female (41.5%); mean age 63.3 ± 15.94 years, range 13–103 years) were included. Results The three most common causes of UGIB were peptic ulcer (38.2%), nonulcer-mucosal lesions (23.4%), and esophageal-related causes (20.4%). The 5 year-incidence of H. pylori was 25%–30%. The overall prevalence was 27%. The prevalence of H. pylori infection was found to decrease with age from 43.8% at <40 years to 21.7% at >79 years old. H. pylori infection was significantly associated with duodenal and gastroduodenal ulcers. Cirrhosis and nonulcer-mucosal lesions were significantly unrelated to H. pylori infection. Patients with concurrent cirrhosis with peptic ulcer were found to be negative for H. pylori infection. Conclusion Peptic ulcer is the leading cause of UGIB in Thailand. However, its incidence is declining. Patients who presented to hospital with UGIB were older, compared with those a decade ago. H. pylori infection plays an important role in UGIB and its incidence was stable during the past 5 years.

scholarly journals Role of Helicobacter pylori in Upper Gastrointestinal Bleeding Among Ischemic Stroke Hospitalizations: A Nationwide Study of Outcomes

2019 ◽  
Vol 1 (3) ◽  
pp. 358-371
Author(s):  
Urvish K. Patel ◽  
Mihir Dave ◽  
Anusha Lekshminarayanan ◽  
Nidhi Patel ◽  
Abhishek Lunagariya ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Ischemic Stroke ◽  
Risk Stratification ◽  
Gastrointestinal Bleeding ◽  
Health Care Cost ◽  
Upper Gastrointestinal Bleeding ◽  
Increased Risk ◽  
H Pylori ◽  
Upper Gastrointestinal

Introduction: Helicobacter pylori (H. pylori) is a well-recognized risk factor for upper gastrointestinal bleeding (UGIB). The exposure to tissue plasminogen activator (tPA), anti-platelets, and anticoagulants increases the risk of UGIB in acute ischemic stroke (AIS) patients, the risk stratification of H. pylori infection is not known. In this retrospective cross-sectional study, we aimed to evaluate the relationship between H. pylori and GIB in patients hospitalized with AIS. Methods: In the nationwide data, hospitalization for AIS was identified by primary diagnosis using International Classification of Diseases, clinical modification (ICD-9-CM) codes. Subgroup of patients with GIB and H. pylori were identified in AIS cohort. A stepwise multivariable logistic regression model was fitted to evaluate the outcome of upper GIB and role of H. Pylori in UGIB. Results: Overall 4,224,924 AIS hospitalizations were identified, out of which 18,629 (0.44%) had UGIB and 3122 (0.07%) had H. pylori. The prevalence of H. pylori-induced UGIB among UGIB in AIS was 3.05%. The prevalence of UGIB was markedly elevated among the H. pylori infection group (18.23% vs. 0.43%; p < 0.0001) compared to the non-H. pylori group. In multivariable regression analysis, H. pylori was associated with markedly elevated odds of UGIB (aOR:27.75; 95%CI: 21.07–36.55; p < 0.0001). Conclusion: H. pylori infection had increased risk-adjusted occurrence of UGIB amongst the AIS hospitalized patients. H. pylori testing may improve risk stratification for UGIB and lower the health care cost burden in stroke hospitalization.

scholarly journals Significance of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in patients with bleeding from upper part of the gastrointestinal tract

2007 ◽  
Vol 64 (7) ◽  
pp. 445-448
Author(s):  
Gradimir Golubovic ◽  
Ratko Tomasevic ◽  
Biljana Radojevic ◽  
Aleksandar Pavlovic ◽  
Predrag Dugalic
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Ulcer Bleeding ◽  
Significant Difference ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
H Pylori ◽  
Upper Gastrointestinal

Background/Aim. Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inflammatory drugs (NSAIDs) use are considered to be the most important risk factors having influence on the onset of bleeding gastroduodenal lesions. Whether there is an interaction between H. pylori infection and the use of NSAIDs in the development of peptic ulcer disease is still controversial. The aim of the present study was to evaluate the prevalence of NSAIDs use and H. pylori infection in patients presented with bleeding gastroduodenal lesions. Methods. During the period from January 2003 - December 2003 we prospectively obtained data of all the patients (n=106) presented with signs of upper gastrointestinal bleeding. All the patients were admitted to the intensive care unit, with the endoscopy performed within 12 hours after admission. Histologic analysis was used for the detection of H. pylori infection. The NSAIDs and aspirin use data were obtained by anamnesis. Results. The results of our study revealed that the most common sources of upper gastrointestinal bleeding were duodenal (57 patients, 53.77%) and ventricular (36 patients, 33.96%) ulcers. The majority of the examined cases were associated with both H. pylori infection and NSAIDs use. A statistically significant difference among the studied groups of patients was proven. Conclusion. The majority of bleeding gastroduodenal lesions were associated with the coexistence of H. pylori infection and NSAIDs use, while their independent influences were statistically less important. Eradication of H. pylori infection in patients using NSAIDs might prevent upper gastrointestinal hemorrhage and reduce peptic ulcer bleeding risk. .

scholarly journals Ūmino nevarikozinio kraujavimo įvertinimo ir stabdymo protokolas

2005 ◽  
Vol 3 (1) ◽  
pp. 0-0
Author(s):  
Jonas Valantinas
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Bleeding ◽  
Variceal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Eradication Therapy ◽  
Optimal Timing ◽  
Practical Recommendation ◽  
Early Endoscopy ◽  
Management Recommendations ◽  
Upper Gastrointestinal

Jonas ValantinasVilniaus universiteto Medicinos fakultetoGastroenterologijos, nefrologijos, urologijosir abdominalinės chirurgijos klinika,Santariškių g. 2, LT-08661, VilniusEl paštas: [email protected] Per pastaruosius dešimt metų ūminio nevarikozinio kraujavimo stabdymo metodai pasikeitė. Straipsnyje apžvelgiame šiuolaikinius viršutinės virškinimo trakto dalies kraujavimo metodus, kurie patvirtinti klinikiniais tyrimais grįstomis išvadomis. Esant viršutinės virškinimo trakto dalies kraujavimui, pirmiausia tenka atkurti cirkuliuojančio kraujo tūrį ir, pasikonsultavus su internistu bei chirurgu, nustatyti ankstyvo endoskopinio tyrimo indikacijas. Nors endoskopinio tyrimo reikšme šiuo metu niekas neabejoja, jo atlikimo laikas turi būti nustatomas individualiai. Endoskopinė hemostazė atliekama pacientams, kuriems pakartotinio kraujavimo rizika yra didelė. Sustabdžius kraujavimą, gydymas protonų siurblio inhibitoriais naudingas tik daliai ligonių, kuriems nustatomi ankstyvo pakartotinio kraujavimo endoskopiniai požymiai (matoma nekraujuojanti kraujagyslė, krešulys opos dugne ar aktyvus kraujavimas atliekant endoskopiją). Kraujuojantys ligoniai turi būti ištirti ieškant Helicobacter pylori infekcijos. Nustačius infekciją skiriamas eradikacinis gydymas. Ši apžvalga yra rekomenduojamojo pobūdžio ir gydymo įstaigos turi sudaryti joms priimtinus kraujavimo stabdymo protokolus, atsižvelgdamos į savo išteklius. Reikšminiai žodžiai: ūminis nevarikozinis kraujavimas, kraujavimo stabdymas, endoskopinis tyrimas Acute non-variceal bleeding assessment and hemostasis protocol (A PRACTICAL RECOMMENDATION) Jonas ValantinasVilnius University, Faculty of Medicine Clinic of Gastroenterology,Nephrology, Urology and Abdominal Surgery,Santariškių str. 2, LT-08661 Vilnius, LithuaniaE-mail: [email protected] The management of patients with acute non-variceal upper gastrointestinal bleeding has evolved substantially over the past ten years. This article reviews the currently available treatment methods in cases of upper gastrointestinal bleeding and provides evidence-based management recommendations that address clinically relevant issues. We emphasise an appropriate initial resuscitation of the patient and a multidisciplinary approach to clinical risk stratification that determines the need for early endoscopy. A soon as the effectiveness of upper endoscopy has been established, its optimal timing has to be clearly defined. Endoscopic hemostasis is reserved for patients with high rebleeding risk endoscopic lesions. Routine second look endoscopy is not recommended. Proton pomp inhibitors therapy is useful only in a selected group of patients, namely those with ulcers having endoscopic high risk stigmata of rebleeding (nonbleeding visible vessel, adherent clot or active bleeding at the time of endoscopy). Patients with upper gastrointestinal bleeding should be tested for Helicobacter pylori infection and receive eradication therapy if infection is present. This review should be considered as a recommendation and hospitals should develop institution-specific protocols according to their resources. Keywords: acute non-variceal bleeding, haemostasis, endoscopy

scholarly journals Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Case–Control Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Marcela Forgerini ◽  
Gustavo Urbano ◽  
Tales Rubens de Nadai ◽  
Sabrina Setembre Batah ◽  
Alexandre Todorovic Fabro ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Bleeding ◽  
Genetic Variants ◽  
Case Control Study ◽  
Upper Gastrointestinal Bleeding ◽  
Case Control ◽  
Gastrointestinal Disorders ◽  
Increased Risk ◽  
Upper Gastrointestinal ◽  
Control Study

Objective: To assess the association between PTGS1 and NOS3 variant alleles and the risk to develop upper gastrointestinal bleeding (UGIB) secondary to complicated peptic disease.Methods: A case–control study was conducted in a Brazilian complex hospital from July 2016 to March 2020. Case: Patients with UGIB diagnosis. Control: Patients admitted for surgery not related to gastrointestinal disorders. Variables: UGIB (outcome), genetic variants in PTGS1 and NOS3 genes (independent), and sex, age, schooling, ethnicity, previous history of gastrointestinal disorders, Helicobacter pylori serology, comorbidity, drug therapy, and lifestyle (confounding). The single-nucleotide polymorphisms (SNPs) of the PTSG1 gene (rs1330344, rs3842787, rs10306114, and rs5788) and NOS3 gene (rs2070744 and rs1799983) were determined using the real-time polymerase chain reaction. Helicobacter pylori serology was determined through the chemiluminescence technique. Logistic regression models were built and deviations of allelic frequencies from Hardy–Weinberg equilibrium were verified.Results: 200 cases and 706 controls were recruited. Carriers of the AG genotype of rs10306114 (OR: 2.55, CI 95%: 1.13–5.76) and CA + AA genotypes of rs5788 (OR: 2.53, CI 95%: 1.14–5.59) were associated with an increased risk for the UGIB development. In nonsteroidal anti-inflammatory drugs (NSAIDs) users, the six variants evaluated modified the magnitude of the risk of UGIB, whereas in low-dose aspirin (LDA) users, an increased risk of UGIB was observed for four of them (rs1330344, rs10306114, rs2070744, and rs1799983). Personal ulcer history (p-value: &lt; 0.001); Helicobacter pylori infection (p-value: &lt; 0.011); NSAIDs, LDA, and oral anticoagulant use (p-value: &lt; 0.001); and alcohol intake (p-value: &lt; 0.001) were also identified as independent risk factors for UGIB.Conclusion: This study presents two unprecedented analyses within the scope of the UGIB (rs10306114 and rs2070744), and our findings showing an increased risk of UGIB in the presence of the genetic variants rs10306114 and rs5788, regardless of the drug exposure. Besides, the presence of the evaluated variants might modify the magnitude of the risk of UGIB in LDA/NSAIDs users. Therefore, our data suggest the need for a personalized therapy and drug use monitoring in order to promote patient safety.

Sign in / Sign up

Export Citation Format

Share Document